Feed aggregator

The new Fellows have been recognised for their remarkable contributions to advancing medical science, groundbreaking research discoveries and translating developments into benefits for patients and the wider public. Their work exemplifies the Academy’s mission to create an open and progressive research sector that improves health for everyone.

They join an esteemed Fellowship of 1,450 researchers who are at the heart of the Academy’s work, which includes nurturing the next generation of scientists and shaping research and health policy in the UK and worldwide.

One of Cambridge’s new Fellows, Professor Sam Behjati, is a former recipient of the Academy’s prestigious Foulkes Foundation medal, which recognises rising stars within biomedical research. Sam is Clinical Professor of Paediatric Oncology at the University and an Honorary Consultant Paediatric Oncologist at Addenbrooke’s Hospital, as well as Group Leader at the Wellcome Sanger Institute. His research is rooted in cancer genomics, phylogenetics, and single cell transcriptomics and spans a wide range of diseases and biological problems. More recently, his work has focused on the origin of cancers, in particular of childhood cancer. In addition, he explores how to use genomic data to improve the treatment of children. Sam is a Fellow at Corpus Christi College, Cambridge.

Also elected to the Academy of Medical Sciences Fellowship are:

Professor Clare Bryant, Departments of Medicine and Veterinary Medicine

Clare Bryant is Professor of Innate Immunity. She studies innate immune cell signalling during bacterial infection to answer fundamental questions about host-pathogen interactions and to search for new drugs to modify them. She also applies these approaches to study inflammatory signalling in chronic diseases of humans and animals.  Clare has extensive collaborations with many pharmaceutical companies, is on the scientific advisory board of several biotech companies, and helped found the natural product company Polypharmakos. Clare is a Fellow of Queens’ College, Cambridge.

Professor Frank Reimann, Institute of Metabolic Science-Metabolic Research Laboratories

Frank Reimann is Professor of Endocrine Signaling. The main focus of his group, run in close partnership with Fiona Gribble, is the enteroendocrine system within the gut, which helps regulate digestion, metabolism, and how full we feel. Their work has included the use of animal models and human cellular models to understand how cells function. One of these cells, glucagon-like peptide-1 (GLP-1) is the target of therapies now widely used in the treatment of diabetes mellitus and obesity. How cells shape feeding behaviour has become a major focus of the lab in recent years.

Professor Mina Ryten, UK Dementia Research Institute

Mina Ryten is a clinical geneticist and neuroscientist, and Director of the UK Dementia Research Institute at Cambridge since January 2024. She also holds the Van Geest Professorship and leads a lab focused on understanding molecular mechanisms driving neurodegeneration. Mina’s research looks at how genetic variation influences neurological diseases, particularly Lewy body disorders. Her work has advanced the use of single cell and long-read RNA sequencing to map disease pathways and identify potential targets for new treatments. Her expertise in clinical care and functional genomics has enabled her to bridge the gap between patient experience and scientific discovery.

Professor Andrew Morris CBE FRSE PMedSci, President of the Academy of Medical Sciences, said: “The breadth of disciplines represented in this year’s cohort – from mental health and infectious disease to cancer biology and respiratory medicine – reflects the rich diversity of medical science today. Their election comes at a crucial time when scientific excellence and collaboration across disciplines are essential for addressing global health challenges both now and in the future. We look forward to working with them to advance biomedical research and create an environment where the best science can flourish for the benefit of people everywhere.”

The new Fellows will be formally admitted to the Academy at a ceremony on Wednesday 9 July 2025.

Four Cambridge biomedical and health researchers are among those announced today as newly-elected Fellows of the Academy of Medical Sciences.

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Infect Dis Model. 2025 Apr 23;10(3):924-934. doi: 10.1016/j.idm.2025.04.005. eCollection 2025 Sep.

ABSTRACT

Effective communication of modelling results to policy and decision makers has been a longstanding challenge in times of crises. This communication takes many forms - visualisations, reports, presentations - and requires careful consideration to ensure accurate maintenance of the key scientific messages. Science-to-policy communication is further exacerbated when presenting fundamentally uncertain forms of science such as infectious disease modelling and other types of modelled evidence, something which has been understudied. Here we assess the communication and visualisation of infectious disease modelling results to national COVID-19 policy and decision makers in 13 different countries. We present a synthesis of recommendations on what aspects of visuals, graphs, and plots policymakers found to be most helpful in their COVID-19 response work. This work serves as a first evidence base for developing guidelines on the communication and translation of infectious disease modelling into policy.

PMID:40390802 | PMC:PMC12088752 | DOI:10.1016/j.idm.2025.04.005

Nat Commun. 2025 May 17;16(1):4605. doi: 10.1038/s41467-025-59757-4.

ABSTRACT

Due to its climatic variability, complex mobility networks and geographic expanse, the United States represents a compelling setting to explore the transmission processes that lead to heterogeneous yearly seasonal influenza epidemics. By analyzing genomic and epidemiological data collected in the US from 2014 to 2023, we show that epidemics consisted of multiple co-circulating transmission lineages that could emerge from all regions and often rapidly expanded. Lineage spread was characterized by strong spatiotemporal hierarchies and lineage size correlated with timing of establishment in the US. Mechanistic epidemic simulations, supported by phylogeographic analyses, suggest that competition between lineages on a network of human mobility consistent with commuting flows drove lineage dynamics. Our results suggest that the processes that disseminate viruses nationwide are highly structured, but variability in the short-term processes that determine the locations, timing, and explosiveness of initial epidemic sparks limits predictability of regional and national epidemics.

PMID:40382319 | DOI:10.1038/s41467-025-59757-4

J Vet Intern Med. 2025 May-Jun;39(3):e70077. doi: 10.1111/jvim.70077.

ABSTRACT

BACKGROUND: Diagnosing epilepsy and dyskinesia in dogs relies on seizure semiology, laboratory workup, brain imaging, and electroencephalography. Variability in existing epilepsy surveys complicates comparison and impedes epidemiologic and genetic research.

OBJECTIVE: To characterize the semiology of epileptic seizures and dyskinesia episodes using a novel, owner-completed, multi-language online questionnaire.

ANIMALS: A cohort of 606 dogs from 96 breeds with paroxysmal events, perceived by their owners as epilepsy or dyskinesia.

MATERIALS AND METHODS: A comprehensive epilepsy and dyskinesia questionnaire featuring pragmatic seizure categories and video upload was developed in German, Finnish, and English. The reliability of the questionnaire was assessed, and the study cohort analyzed.

RESULTS: The questionnaire demonstrated strong internal consistency and interrater agreement. Owners correctly classified paroxysmal events in 90.1% of cases (95% CI 88.18-92.11). Video footage was submitted from 23.8% (143/606) and supported the seizure type in the questionnaire in 96.5%. The age of onset ranged from 6 months to 6 years in 80.2% (median 2 years; IQR 1-5 years). Generalized (epileptic) convulsive seizures occurred in 58.6% of dogs, non-generalized paroxysmal motor events without convulsions in 58.1%, sudden falls without movement in 6.1%, episodes of impaired awareness in 15.8%, and other unclassified events in 7.1%. Multiple seizure types were reported in 25.2% of the dogs. Labrador Retrievers exhibited a higher prevalence of non-generalized motor events compared to Border Collies, Siberian Huskies, and other breeds (p < 0.001).

CONCLUSIONS: The questionnaire reliably characterizes epileptic seizures and dyskinesia episodes in dogs, making it a valuable tool for large-scale epidemiological and genetic studies.

PMID:40375574 | DOI:10.1111/jvim.70077

Vet J. 2025 May 13:106372. doi: 10.1016/j.tvjl.2025.106372. Online ahead of print.

ABSTRACT

The impact of brachycephalic obstructive airway syndrome in dogs (BOAS) on respiratory mechanics is unclear and may affect the choice of ventilation strategies during anaesthesia. This prospective study included 56 client-owned brachycephalic dogs, allocated to be BOAS (n = 26) or non-BOAS dogs (n = 30) based on functional grading. All dogs were anaesthetised using a standardised anaesthetic protocol. Pressure-controlled ventilation was initiated around 30minutes post-induction, maintaining peak inspiratory pressure at 7-12cm H2O. Static respiratory compliance (Cstat) was recorded at predetermined time points in sternal, right and left lateral recumbency. Thorax dimensions were assessed with a tape measure. Body surface area (BSA) was calculated and the ratio Cstat/BSA used as the main outcome variable. Comparison of means/medians, analysis of proportions, the Spearman correlation coefficient and both logistic and linear regression were used for data analysis. P < 0.05 was considered statistically significant. Non-BOAS dogs showed significantly higher Cstat/BSA compared to BOAS dogs in sternal (41.6 (31.1-51.8) vs. 32.9 (24.4 - 39.2), respectively, P = 0.028), right lateral (36.2 (25.7 - 46.4) vs. 27.0 (22.7 - 35.6); P = 0.026) and left lateral (33.6 (22.6 - 45.5) vs. 24.6 (18.4 - 32.2); P = 0.020) recumbencies. For all dogs, the Cstat/BSA ratio was higher in sternal compared to lateral recumbencies. BOAS dogs had a significantly shorter distance between thoracic inlet and last rib compared to non-BOAS dogs (20 ± 4 vs. 23 ± 6cm, respectively; P = 0.043). Reduced respiratory compliance in BOAS-affected dogs should be considered during mechanical ventilation.

PMID:40374099 | DOI:10.1016/j.tvjl.2025.106372

Vet Comp Orthop Traumatol. 2025 May 8. doi: 10.1055/a-2591-7747. Online ahead of print.

ABSTRACT

To use kinetic and kinematic analysis to determine whether a cementless femoral implanted with a bioactive coating can be an effective alternative to a cemented femoral stem.In the Cemented group, six dogs were implanted with a 316L stainless steel hip prosthesis. The six dogs in the Cementless group were implanted with a 316L stainless steel hip prosthesis with a biphasic calcium phosphate coating. Kinetic gait analysis was performed before the surgery and at 2, 4, 6, 8, and 12 weeks postoperatively. Kinematic analyses were carried out before the surgery and at 2, 4, 6, 8, 12, and 16 weeks.A slow and sustained improvement in kinetic parameters occurred over time. Dogs implanted with the cemented prosthesis recovered normal preoperative values for maximal hip extension angle by 4 weeks after surgery. Dogs with cementless prosthesis had not recovered normal hip extension by 4 weeks. Despite this short-term change in hip mobility, there were no significant differences in gait between the two groups over the 4-month study period.No differences in gait between cementless and cemented prosthesis were observed throughout the postoperative period to the fourth month. Additionally, compensation and adaptation with gradual recovery of kinetic and kinematic parameters were evident.

PMID:40341514 | DOI:10.1055/a-2591-7747

Emerg Microbes Infect. 2025 May 6:2502011. doi: 10.1080/22221751.2025.2502011. Online ahead of print.

NO ABSTRACT

PMID:40326334 | DOI:10.1080/22221751.2025.2502011

The department wishes to appoint a Clinical Skills Manager and Teaching Associate from 1 September 2025, or as soon as possible thereafter.

This is an exciting opportunity to teach veterinary clinical skills and to manage a small team, ensuring the effective management of Clinical Skills teaching and facilities in the Department.

You will deliver clinical skills practical teaching, and co-ordinate the teaching of other members of the Clinical Skills team. You will also collaborate with clinicians in the Queen's Veterinary School Hospital to deliver aspects of the veterinary programme. Your teaching is currently focused on small animal clinical skills but may also include equine and farm animal skills, and you will be supported in developing new skills.

Clinical Skills Teaching includes (but is not limited to): clinical skills staff-led classes (clinical examination, suturing, anaesthesia), clinician-led clinical skills classes (e.g., cardiopulmonary resuscitation, neurology), student self-directed learning, peer-to-peer teaching initiatives, provision of additional drop-in sessions where you will work one-to-one with students, to maximize the educational potential of the clinical skills facilities and preparation of online learning material delivered through the University's virtual learning environment.

You will contribute to curriculum design, actively support the development of online teaching material for Clinical Skills and will help to devise and deliver practical assessment circuits (Objective Structured Clinical Exams or OSCEs) in partnership with academic colleagues.

You will coordinate the development of standard operating procedures, risk assessments and health and safety within the Clinical Skills area in line with Departmental policy and is assigned a small operating budget by the Teaching Operations Committee. You will also be encouraged to contribute to veterinary education conferences on behalf of the Department alongside other members of the team.

You will be required to attend on site during Full Terms of the Department of Veterinary Medicine, and other weeks outside of term for specific tasks (including examination preparation and outreach activities) throughout the year. Outside of those times, remote working, up to one day a week would be considered.

It is essential that applicants are:

Registered Veterinary Nurse or Veterinary Surgeon Have significant post-registration clinical experience and should be confident in practical skills to underpin delivery of clinical skills education to veterinary students Skilled and experience in staff management and supervision Applicants should have excellent organisational skills, the ability to organise their own time and have experience in the training of veterinary nurses or veterinary students, with the ability to address skills learning and assessment in a creative way

Experience in using and having responsibility for care and maintenance of a range of equipment commonly used in veterinary practice

Desirable qualities include:

Relevant teaching qualification (AFHEA and/or FHEA) Post graduate qualifications in medical / veterinary / clinical education or a willingness to work towards these Experience in FE and/or HE education Undergraduate teaching experience, both large and small group teaching Experience in practical assessment and OSCE examination, design and delivery. Have education sector skills to included session planning, writing schemes of work and quality assurance

Informal enquiries should be directed to Dr Hannah Wong by email hew28@cam.ac.uk

Click the 'Apply' button below to register an account with our recruitment system (if you have not already) and apply online.

Enquiries about the application process can be directed to hr.enquiries@vet.cam.ac.uk

Applicants should submit a CHRIS/6, CV, covering letter outlining suitability for the role and contact details for two references. Please ensure that you upload your Curriculum Vitae (CV) and a covering letter in the Upload section of the online application. If you upload any additional documents which have not been requested, we will not be able to consider these as part of your application.

For more information about the Department please visit www.vet.cam.ac.uk

Closing date for applications is 3 June 2025. Interviews will be held on 18 June 2025

Please quote reference PP45871 on your application and in any correspondence about this vacancy.

The University actively supports equality, diversity and inclusion and encourages applications from all sections of society.

The University has a responsibility to ensure that all employees are eligible to live and work in the UK.

Microbiol Res. 2025 Apr 25;297:128196. doi: 10.1016/j.micres.2025.128196. Online ahead of print.

ABSTRACT

The globally disseminated Staphylococcus aureus ST5 clone poses a major public health threat due to its multidrug resistance and virulence. Here, we identified an agr-dysfunctional (agrA-I238K) ST5 MRSA clone that has spread across East and Southeast Asia, with recent increases in China since its emergence in the 1970s. Comparative genomic analyses identified distinct single-nucleotide polymorphisms and mobile genetic elements linked to enhanced resistance and virulence. This clone exhibits resistance to seven antimicrobial classes, including third-generation tetracyclines and fusidic acid, and shares phenotypic and genetic similarities with the vancomycin-intermediate S. aureus Mu50 strain, including reduced susceptibility to vancomycin, teicoplanin, and daptomycin. The agrA-I238K mutation attenuates hemolytic activity, increases biofilm formation, and reduces daptomycin susceptibility, suggesting a key role in the clone's success. Our results demonstrate the important role of agrA-I238K mutation in the widespread distribution of agr-dysfunctional MRSA and highlight the importance of genomic surveillance in tracking the spread of agr-dysfunctional ST5 MRSA.

PMID:40311457 | DOI:10.1016/j.micres.2025.128196

Transbound Emerg Dis. 2023 Aug 14;2023:2277409. doi: 10.1155/2023/2277409. eCollection 2023.

ABSTRACT

Dairy production is an important livelihood source for smallholder dairy farmers who produce the majority of milk consumed and traded in Ethiopia. Dairy production is, however, constrained by livestock diseases that impact farm productivity, food safety, and animal welfare. Biosecurity measures (BSM) include all risk reduction strategies designed to avoid the introduction of pathogenic infections from outside and minimise the spread of diseases within dairy herds. This study used a cross-sectional survey to investigate the adoption of BSM in dairy farms in Addis Ababa and Oromia regions of Ethiopia. Using a questionnaire, scores for adopted external and internal BSM were calculated based on the Ghent's University Biocheck tool to compare the performance of different farms in Ethiopia. The weighted external biosecurity score was 49.1%, which was below average (below 50% adoption), while the weighted internal biosecurity score was 55.5%. Low adoption of crucial BSM increases the risk of disease introduction into dairy farms and transmission within herds. Adoption of BSM at the farm level was driven by individual, demographic, and socio-economic drivers, including education, farming system, milk value chain, and farming experience among others. Results of this research reveal low adoption of BSM and the imperative to encourage farmers to implement BSM can lead to a reduction in disease pressures and, thus, a reduction in antibiotic use and increased dairy farms productivity, and improved animal health and welfare. Farmers can be encouraged through proactive engagement with veterinarians and extension professionals. Moreover, creating a favourable policy environment can support farmers to adopt and implement BSM, given the known fact that "prevention is better and cheaper than curing diseases."

PMID:40303828 | PMC:PMC12016702 | DOI:10.1155/2023/2277409

J Vet Intern Med. 2025 May-Jun;39(3):e70113. doi: 10.1111/jvim.70113.

ABSTRACT

BACKGROUND: Myasthenia gravis (MG) is categorized into several subgroups, including seronegative MG. Seronegative human patients are well documented, but seronegative dogs remain clinically uncharacterized and their prevalence unknown.

OBJECTIVES: This study aims to evaluate the clinical presentation, diagnosis, treatment, and outcome of canine MG subgroups.

ANIMALS: One hundred sixty-seven owner-owned dogs diagnosed with MG from three referral centers.

METHODS: Retrospective case series. We classified myasthenic dogs into subgroups, adhering to human guidelines.

RESULTS: We classified 167 dogs into four subgroups: acetylcholine receptor (AChR) antibody-positive generalized (49.7%, n = 83/167), focal (19.2%, n = 32/167) and thymoma-associated MG (9%, n = 15/167) and seronegative MG (22.2%, n = 37/167). Dogs with thymoma-associated MG were older (median 102 months; Interquartile Range (IQR) 96-120; p < 0.001) and seronegative dogs were younger (median 30 months; IQR 11.5-66; p = 0.017), compared to the generalized subgroup (median 67 months; IQR 36-96). Seronegative dogs presented less frequently with megaesophagus, compared to the generalized subgroup (63.8% vs. 85.7%; Odds Ratio 3.4; 95% confidence intervals (C.I.) 1.4-8.9; p = 0.025). Myasthenic dogs' survival time was significantly reduced when thymoma (Hazard Ratio (H.R.) 3.7; 95% C.I. 1.4-9.9; p = 0.028) or esophageal weakness (H.R. 3.8; 95% C.I. 2.0-7.0; p < 0.001) was present. Conversely, a higher likelihood of remission was achieved when esophageal weakness was absent (H.R. 3.8; 95% C.I. 1.4-10.0; p = 0.007).

CONCLUSION AND CLINICAL IMPORTANCE: Dogs with seronegative MG are more common than previously reported. Myasthenic subgroups differ in presentation and outcome, with esophageal weakness key to survival and remission. Diagnostic tests for seronegative dogs and effective treatments for esophageal weakness in myasthenic dogs are urgently needed.

PMID:40298067 | DOI:10.1111/jvim.70113

J Biomed Mater Res A. 2025 May;113(5):e37917. doi: 10.1002/jbm.a.37917.

ABSTRACT

Treatment of orthopedic device-related infection (ORDI) generally requires a combination of medical and surgical interventions for successful treatment outcomes. Many cases are treated with a two-stage revision, whereby contaminated implants and necrotic tissues are removed, and dead space is managed with a temporary, non-resorbable polymethyl methacrylate (PMMA) spacer loaded with antibiotics. Weeks later, this is replaced with a bone graft or similar material to aid bone healing. However, this two-stage approach is quite a burden for the patient, and infection may still recur. The use of a 3D-printed, absorbable, antibiotic-releasing material that also promotes bone healing would be a promising alternative that produces the exact geometry of the missing bone and eliminates the need for a second surgery. In this study, we investigated whether a novel 3D-printed, antibiotic-loaded, osteoconductive calcium phosphate scaffold (CPS) is effective in the single-stage revision of an infected segmental bone defect model in rabbits. A 5-mm segmental defect of the radius of female New Zealand White rabbits (n = 64), stabilized with cerclage wire, was inoculated with Staphylococcus aureus. After 4 weeks, the infected bone fragment was removed, the site debrided, and the bone defect was either left empty (Control group) or filled with a PMMA spacer with gentamicin, CPS loaded with rifampicin or non-loaded CPS. The animals were also managed with systemic cefazolin for 4 weeks. An additional group received vancomycin-loaded CPS without adjunctive systemic antibiotic therapy. All animals were euthanized 8 weeks after revision and assessed by quantitative bacteriology or semiquantitative histopathology. The antibiotic-loaded scaffolds (PMMA-Genta and CPS-Rif) in the animals receiving systemic antibiotic treatment resulted in a reduction in bacterial count at euthanasia compared to controls (rabbits receiving systemic antibiotic alone and in which the defect was left empty). The PMMA-Genta induced a significant CFU reduction (p = 0.0486) compared to controls. The infection rate was also reduced from 80% in the control group to 50% for the groups receiving local and systemic antibiotics. The CPS-Vanco group for local delivery without adjunctive systemic antibiotic therapy resulted in a lower infection rate, but the CFUs in these samples at euthanasia were comparable with those of the control group. The findings show that treating an ODRI with PMMA-Genta yields the best results for infection eradication; however, it does not provide the reconstruction opportunity that the antibiotic-loaded CPS does. Even though it is not comparable to the PMMA-Genta, the antibiotic-loaded CPS showed a reduction in infection rates. The use of local antibiotics alone is insufficient to eradicate the infection.

PMID:40296342 | DOI:10.1002/jbm.a.37917

Scholarship award: £21,970.00 per annum (Tax Exempt), inclusive of the accommodation package.

Start date: from September 2025, or as soon as possible thereafter, for 12 months

Applications are invited for this 12-month Scholarship programme, which provides an opportunity for new graduates or recently qualified veterinarians to receive high-quality postgraduate training in farm animal studies under the supervision of experienced farm animal clinicians in the Cambridge Farm Animal Veterinary Services ambulatory and referral practice at the University of Cambridge. The emphasis of the programme is on gaining practical clinical experience in farm animal medicine and herd health and will allow the Scholar to identify specific fields of farm animal work in which to specialise, either in preparation for Senior Clinical Training Scholarship programmes, or for specialist private practice.

The internship will cover:

• Case involvement of individual production animals, including emergency and critical care, surgery, anaesthesia, diagnostics, internal medicine and obstetrics
• Involvement in a busy and expanding first opinion farm animal practice and referral hospital
• Training and practice in population medicine and herd health management, with an emphasis on evidence-based medicine
• Experience in teaching and communication
• Basic tuition in research methods and scientific writing
• Opportunity to design and undertake research projects

Summary of benefits

• Competitive tax-free stipend including accommodation in Central Cambridge and bills included package
• Good work-life balance with manageable weekend and night work
• University library and journal access
• 2 weeks of elective/dedicated research time on top of holidays
• Academic opportunities, e.g. teach Cambridge students during rotations and College supervisionopportunities; weekly department research and clinical seminars; journal and book clubs
• Proven track-record with publications and research projects with guidance on presentation and scientific writing skills
• Assigned intern supervisor: - regular progress meetings, interview practice, provision of professional references and CV/cover letter proof reading by experienced senior clinicians to aid residency applications
• Generous CPD allowance and encouragement to present at scientific meetings

To learn more about the Farm Animal Veterinary Services and the Department, please visit: https://www.hospital.vet.cam.ac.uk/farm-animal.

Informal enquiries should be directed to: Ian McCrone, by email: ism27@cam.ac.uk.

Applicants must be a Member of the Royal College of Veterinary Surgeons or hold a veterinary degree qualifying them for membership.

A JCTS Application Form (JCTS 1) and Information Pack can be downloaded from the following website: https://www.vet.cam.ac.uk/job.

Applicants should supply a completed Junior Clinical Training Scholarship Application Form (JCTS 1), a CV and Covering Letter giving reasons for wishing to undertake the JCTS in the Department of Veterinary Medicine, University of Cambridge.

Applications should be submitted via e-mail to: vetmed@vet.cam.ac.uk with the above documents as one attachment, by the closing date stated. Please quote reference PP45804 on your application and in any correspondence about this vacancy.

The deadline for applications is midnight on Monday 26th May 2025. Interviews will be held Monday 9th June 2025.

We reserve the right to close this vacancy early if we receive sufficient applications or extend it if we do not receive a sufficient number of applications. Therefore, if you are interested, please submit your application as early as possible.

The University actively supports equality, diversity and inclusion and encourages applications from all sections of society.

Please note: The ability to take up this Scholarship is contingent upon you being able to evidence your right to work in the UK, or through gaining the right to work via the UK immigration system. Evidence will need to be provided before an offer can be made. Regrettably, this Scholarship is not suitable for sponsorship via the Skilled Worker or Temporary Worker visa routes as the minimum requirements cannot be met.

We have an exciting opportunity for a personable and effective administrator to work in the Client Services function of the Queen's Veterinary School Hospital (QVSH). This position is full-time and operates on a rota system to cover the hospital reception's opening hours, which are currently Monday to Friday, 8:00am to 7:00pm.

The Client Service Administrator is the first point of contact within the Small Animal Hospital aiming to provide a first-class customer service, rotating between front desk and telephone to provide all front-of-house services, therefore a friendly, calm and confident communicator is essential. You will be responsible for receiving incoming calls and emails, processing payments, booking appointments, and liaising with clients, referring veterinary practices, QVSH clinicians, nurses and students. You should have experience of working in a busy administrative role, have excellent customer care skills, be numerate, accurate and have an eye for detail.

You must be efficient and experienced in Microsoft Office packages and have the ability to establish professional and effective working relationships with the wider team. Excellent organisation skills, attention to detail and flexibility are all essential parts of the role.

In return, we offer an encouraging and nurturing environment and have a dedicated team of clinicians and nurses who are committed to providing the best care for our patients.

Benefits: - Generous paid annual leave including bank holidays - Defined benefit pension scheme - Enhanced family friendly policies - Access to a dedicated Personal and Professional Development team - Wellness programme including Occupational Health team and Staff counselling - Staff discount scheme including shopping vouchers - Cycle to work scheme - Travel to work loans - Eye care voucher scheme - Discounted gym membership

There may also be a requirement to participate in a weekend working, for which additional remuneration will be made in line with the University Policy.

For informal enquiries please contact the Clinical HR Team, by email on: qvsh.hr@vet.cam.ac.uk. Please quote reference PP45802 on your application and in any correspondence about this vacancy.

Click the 'Apply' button below to register an account with our recruitment system (if you have not already) and apply online.

Please outline in your job application how you meet the essential criteria set out in the Further Particulars.

Further particulars for the role and information about the Department visit: www.vet.cam.ac.uk.

Closing date for applications: Midnight on 11th of May. Interviews will be held on the 21st of May.

We reserve the right to close this vacancy early if we receive sufficient applications or extend it if we do not receive a sufficient number of applications. Therefore, if you are interested, please submit your application as early as possible.

The University actively supports equality, diversity and inclusion and encourages applications from all sections of society.

The University has a responsibility to ensure that all employees are eligible to live and work in the UK.

Proc Natl Acad Sci U S A. 2025 May 6;122(18):e2424634122. doi: 10.1073/pnas.2424634122. Epub 2025 Apr 22.

ABSTRACT

Horizontal transfer of nuclear DNA between cells of host and cancer is a potential source of adaptive variation in cancer cells. An understanding of the frequency and significance of this process in naturally occurring tumors is, however, lacking. We screened for this phenomenon in the transmissible cancers of dogs and Tasmanian devils and found an instance in the canine transmissible venereal tumor (CTVT). This involved introduction of a 15-megabase dicentric genetic element, composed of 11 fragments of six chromosomes, to a CTVT sublineage occurring in Asia around 2,000 y ago. The element forms the short arm of a small submetacentric chromosome and derives from a dog with ancestry associated with the ancient Middle East. The introduced DNA fragment is transcriptionally active and has adopted the expression profile of CTVT. Its features suggest that it may derive from an engulfed apoptotic body. Our findings indicate that nuclear horizontal gene transfer, although likely a rare event in tumor evolution, provides a viable mechanism for the acquisition of genetic material in naturally occurring cancer genomes.

PMID:40261943 | DOI:10.1073/pnas.2424634122

Vet Microbiol. 2025 Apr 11;305:110509. doi: 10.1016/j.vetmic.2025.110509. Online ahead of print.

ABSTRACT

Glaesserella parasuis is the causative agent of Glässer's disease in pigs and results in significant losses to the swine industry annually. Due to the serovar and strain specific response associated with many bacterin vaccines, there has been difficulty generating broad heterologous protection. Here, an unencapsulated G. parasuis mutant (HS069∆cap) was assessed as a bacterin vaccine and compared to a bacterin made from the encapsulated parent strain, against challenge with the homologous, parent strain (serovar 5) as well as four heterologous challenge strains (serovar 1, 4, 5, and 14). Both the HS069 and HS069∆cap bacterins generated high titers to the homologous and heterologous strains. The HS069∆cap bacterin was able to provide protection against the parent strain as well as 12939 (serovar 1), 2170B (serovar 4), and MN-H (serovar 13), but was unable to protect animals from challenge with Nagasaki (serovar 5). In contrast, the HS069 bacterin was able to provide protection against all challenge strains, showing the importance of serovar specific immunity against the challenge strain Nagasaki. This appears to be due to the production of a more abundant and well-organized capsule in Nagasaki as compared to HS069. This study indicates HS069∆cap is a good candidate strain for bacterin development; however, it may be less able to provide protection against highly encapsulated strains of G. parasuis.

PMID:40250105 | DOI:10.1016/j.vetmic.2025.110509

Pharmacogenomics J. 2025 Apr 17;25(3):9. doi: 10.1038/s41397-025-00367-0.

ABSTRACT

Similarity between candidate drug targets and human proteins is commonly assessed to minimize the occurrence of side effects. Although numerous drugs have been found to disrupt the health of the human microbiome, no comprehensive comparison between established drug targets and the human microbiome metaproteome has yet been conducted. Therefore, herein, sequence and structure alignments between human and pathogen drug targets and representative human gut, oral, and vaginal microbiome metaproteomes were performed. Both human and pathogen drug targets were found to be similar in sequence, function, structure, and drug binding capacity to proteins in diverse pathogenic and non-pathogenic bacteria from all three microbiomes. The gut metaproteome was identified as particularly susceptible overall to off-target effects. Certain symptoms, such as infections and immune disorders, may be more common among drugs that non-selectively target host microbiota. These findings suggest that similarities between human microbiome metaproteomes and drug target candidates should be routinely checked.

PMID:40246834 | DOI:10.1038/s41397-025-00367-0

Hemasphere. 2025 Apr 16;9(4):e70113. doi: 10.1002/hem3.70113. eCollection 2025 Apr.

ABSTRACT

The treatment of chronic neutropenias and control of neutropenia-related infections remain challenging topics for pediatric and adult hematologists. This article aims to fill the gap in the treatment of neutropenias and, in combination with the previously published European guidelines on diagnosis of neutropenias, gives complete and comprehensive guidance on the whole management of patients with neutropenia. In terms of methodology, an Evidence-Based Medicine team produced an evidence synthesis of the literature on the treatment of neutropenias. Then, according to the robustness of the evidence, consensus recommendations were elaborated and voted by an expert's panel from the Cooperation in Science and Technology European Network for the Innovative Diagnosis and Treatment of Chronic Neutropenias (https://eunet-innochron.eu/) and the Specialized Working Group on Granulocytes and Constitutional Bone Marrow Failure Syndromes of the European Hematology Association. Whenever evidence was not available, recommendations were based on the expert's panel opinion. Consensus-based recommendations are related to granulocyte colony-stimulating factor indications and schedule of administration, indications for hematopoietic stem cell transplantation, supportive treatments and measures, and new treatments that have been evolving over the recent years. These guidelines, rather than a numerical correction of the absolute neutrophil count, suggest a holistic, patient-centered approach aiming at optimizing the management of chronic neutropenic patients and offering valuable and practical guidance to the hematologists for their daily clinical practice.

PMID:40242664 | PMC:PMC12001981 | DOI:10.1002/hem3.70113

Parasitology. 2025 Apr 14:1-5. doi: 10.1017/S0031182025000125. Online ahead of print.

NO ABSTRACT

PMID:40223707 | DOI:10.1017/S0031182025000125

Sci Adv. 2025 Apr 11;11(15):eadp8504. doi: 10.1126/sciadv.adp8504. Epub 2025 Apr 11.

ABSTRACT

RNA editing is a posttranscriptional mechanism that targets changes in RNA transcripts to modulate innate immune responses. We report the role of astrocyte-specific, ADAR1-mediated RNA editing in neuroinflammation in Parkinson's disease (PD). We generated human induced pluripotent stem cell-derived astrocytes, neurons and cocultures and exposed them to small soluble alpha-synuclein aggregates. Oligomeric alpha-synuclein triggered an inflammatory glial state associated with Toll-like receptor activation, viral responses, and cytokine secretion. This reactive state resulted in loss of neurosupportive functions and the induction of neuronal toxicity. Notably, interferon response pathways were activated leading to up-regulation and isoform switching of the RNA deaminase enzyme, ADAR1. ADAR1 mediates A-to-I RNA editing, and increases in RNA editing were observed in inflammatory pathways in cells, as well as in postmortem human PD brain. Aberrant, or dysregulated, ADAR1 responses and RNA editing may lead to sustained inflammatory reactive states in astrocytes triggered by alpha-synuclein aggregation, and this may drive the neuroinflammatory cascade in Parkinson's.

PMID:40215316 | DOI:10.1126/sciadv.adp8504